Navigation Links
Xanodyne's New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
Date:4/2/2009

NEWPORT, Ky., April 2 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status for its investigational proprietary formulation of tranexamic acid for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms. On January 30, 2009, Xanodyne submitted the New Drug Application (NDA) for XP12B, a unique oral therapy which acts as a competitive plasmin inhibitor to prevent fibrinolysis by binding to the lysine receptor sites of plasminogen. This helps to normalize the hyperfibrinolytic activity often present in women with HMB.

"We are pleased with the position that the FDA has taken in granting XP12B a priority review as it reflects their recognition of the important unmet medical need which HMB represents. We look forward to working closely with the agency to further advance this important treatment option to women who suffer from menorrhagia, or heavy menstrual bleeding," said Gary A. Shangold, Chief Medical Officer of Xanodyne.

Under the Prescription Drug User Fee Act (PDUFA), drug products with priority review designation have a 6 month review clock as compared to a 10 month standard review. Upon approval, this product candidate could become the first approved pharmaceutical product in the United States specifically indicated for the treatment of menorrhagia.

About Menorrhagia

HMB, or menorrhagia, represents a frequent and significant medical condition encountered by obstetricians, gynecologists and primary care physicians. Menorrhagia has been described as regular, normal intervals of menstruation with excessive volume that may exceed 80 milliliters of blood loss per menstrual cycle. At present, no pharmacotherapy has ever been approved by the FDA for the treatment of this disorder.

About Xanodyne

Xano
'/>"/>

SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Upcoming Symposium to Bridge the Gap between Osteoporosis Research and its Applications to Clinical Practice with Focus on Secondary Osteoporosis, Osteoporosis in Men, and Lessons from Space Travel for Improving Bone Health
2. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
3. GlobalMedia Provides Free Grant Writing and Application Assistance to Healthcare Providers and Professionals Seeking Their Share of Billions in Economic Stimulus Dollars
4. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
5. Hollow gold nanospheres show promise for biomedical and other applications
6. Call for Presentations: Applications of High-Power Semiconductor Lasers Conference & Exhibit
7. FDA Clears Cellectars IND Application for Lead Drug Candidate
8. FDA Halts New Applications From Indian Drug Makers Plant
9. CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application
10. Nephros Provides Update on 510k Applications
11. IMRIS announces development program for MR guided radiation and interventional applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... MJNational LLC strengthens its consultant agreement ... Bizcard ™ platform. This exciting new SMS platform creates ... Sales / Services. Now you can reach out ... products, services and ticker symbol through an easy to ... LLC will provide managed support and services to advance ...
(Date:5/6/2015)... Angeles, CA (PRWEB) May 06, 2015 ... “16 Celebrities on Plastic Surgery ,” compiled quotes ... celebs includes Jennifer Aniston, pop singer Iggy Azalea, and ... indicates their sentiments about having plastic surgery ... statement about society and its expectations of youth and ...
(Date:5/6/2015)... May 06, 2015 Corporate Executives ... of MEBC, an Alliance Award for excellence in ... FOCUS 2015, JDA’s annual user conference which brought ... and wholesale distribution sectors. This award recognizes MEBC, ... receiving services that advance their supply chain performance ...
(Date:5/6/2015)... May 06, 2015 Baptist Medical ... the first in north Florida and southeast Georgia ... the latest innovation in total hip replacement surgery ... surgeon-controlled robotic arm that enables the accurate alignment ... Jacksonville has offered MAKOplasty® partial knee resurfacing using ...
(Date:5/6/2015)... May 06, 2015 “ SideChef ” was featured ... look at the latest and coolest applications on the market for ... technology expert, conducted the app review and shared with viewers how ... the day when to be a good navigator people had to ... and now everyone is a master navigator. Well what if people ...
Breaking Medicine News(10 mins):Health News:Cannabiz Mobile Inc. Launches the Canna Bizcard ™ Platform to Support to Cannabis Market 2Health News:Cannabiz Mobile Inc. Launches the Canna Bizcard ™ Platform to Support to Cannabis Market 3Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 2Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 4Health News:An Application to Guide Users through Recipes Was Featured on NewsWatch Television 2
... a Chinese by origin and a hunter by profession was the ... of now the doctors say that his condition is stable but ... It is one of a kind operation done in china. The ... critical period and is recovering well. He is thirty years old ...
... Mumps is a viral infection and spreads by air ... number of mumps cases. // Statistics show that more ... cases), Nebraska (139), Kansas (205), Illinois (110), Wisconsin (more ... About sixty-seven out of 99 counties have witnessed at ...
... Chess champion and grandmaster Vishwanathan Anand will now champion the cause ... and Melinda Gates Foundation. // ,Anand ... in India for Avahan's public education campaigns. He is already ... new role is likely to help the campaign against AIDS to ...
... one of the leading company which manufactures contact lens solution. ... infections in some users. // After this report ... & Lomb facilities. There was extensive microbiological testing conducted which ... culprit behind the eye infection. Bausch & Lomb stopped shipping ...
... School of Public Health and The Children's Health Fund had ... of sufferers of hurricanes Katrina and Rita are now in ... serious medical and mental health problems, but receiving little or ... from Congress to respond to this looming health crisis. ...
... the past year, raising fears of a surge of sexually-transmitted ... cases. // It is estimated that nearly 350,000 people ... crossed one million. ,What Russia needs to do on ... services for the infected people. It is said that only ...
Cached Medicine News:Health News:Mumps Fever Spreads Unabated In US 2Health News:Chess Champion Anand to Champion HIV/AIDS for Avahan 2Health News:After the hurricane it is the turmoil caused by health problems for victims 2
(Date:5/6/2015)... BEIJING, May 6, 2015 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in China, today ... of 2015. First Quarter 2015 Financial ... quarter of 2015 increased by 25.0% to $70.4 million ... , Gross profit increased by 18.9% to $45.9 ...
(Date:5/6/2015)... May 6, 2015 Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... the investment community to review the clinical development ... cord injury on Friday, May 8, 2015. Topics ... and future planned clinical activities for AST-OPC1. ...
(Date:5/6/2015)... -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today ... 2015.  The net loss and the loss from operations ... million, respectively, compared to $10.7 million and $8.8 million ... 31, 2015, Alexza had consolidated cash, cash equivalents, marketable ... "We continue to focus on ways in which to ...
Breaking Medicine Technology:China Biologic Reports Financial Results for the First Quarter of 2015 2China Biologic Reports Financial Results for the First Quarter of 2015 3China Biologic Reports Financial Results for the First Quarter of 2015 4China Biologic Reports Financial Results for the First Quarter of 2015 5China Biologic Reports Financial Results for the First Quarter of 2015 6China Biologic Reports Financial Results for the First Quarter of 2015 7China Biologic Reports Financial Results for the First Quarter of 2015 8China Biologic Reports Financial Results for the First Quarter of 2015 9China Biologic Reports Financial Results for the First Quarter of 2015 10China Biologic Reports Financial Results for the First Quarter of 2015 11China Biologic Reports Financial Results for the First Quarter of 2015 12China Biologic Reports Financial Results for the First Quarter of 2015 13China Biologic Reports Financial Results for the First Quarter of 2015 14China Biologic Reports Financial Results for the First Quarter of 2015 15China Biologic Reports Financial Results for the First Quarter of 2015 16China Biologic Reports Financial Results for the First Quarter of 2015 17China Biologic Reports Financial Results for the First Quarter of 2015 18Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 2Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 3Alexza Reports 2015 First Quarter Financial Results 2Alexza Reports 2015 First Quarter Financial Results 3Alexza Reports 2015 First Quarter Financial Results 4Alexza Reports 2015 First Quarter Financial Results 5Alexza Reports 2015 First Quarter Financial Results 6Alexza Reports 2015 First Quarter Financial Results 7Alexza Reports 2015 First Quarter Financial Results 8Alexza Reports 2015 First Quarter Financial Results 9Alexza Reports 2015 First Quarter Financial Results 10
... announced today the successful submission of an IND application ... clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ... first quarter of 2009. IQP-0410 is a novel small ... nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a ...
... from prior U.S., U.K. and China TrialsSAN DIEGO, Jan. ... company targeting liver disease, today announced patient enrollment has ... trial that will study the Extracorporeal Liver Assist Device ... Failure (ALF) under three protocols. The study is open ...
Cached Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection Tubes ... Available for a wide range of applications, ... a capillary tube, attached cap and a ... to draw the blood into the micro ...
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection ... systems. Available for a wide range of ... with a capillary tube, attached cap and ... action to draw the blood into the ...
... serology for Toxoplasmosis has progressed ... specialized dye test to immunoflourescence, ... techniques. In addition to ... offers both Toxo IgM immunocapture ...
Serology provides a minimally-invasive, sensitive and easy-to-perform method for the determination of H. pylori infection. The Bio-Rad H. pylori qualitative test kits use EIA technology for the deter...
Medicine Products: